CN112656759B - Rudexilvir eye drops and preparation method and application thereof - Google Patents
Rudexilvir eye drops and preparation method and application thereof Download PDFInfo
- Publication number
- CN112656759B CN112656759B CN202110092173.0A CN202110092173A CN112656759B CN 112656759 B CN112656759 B CN 112656759B CN 202110092173 A CN202110092173 A CN 202110092173A CN 112656759 B CN112656759 B CN 112656759B
- Authority
- CN
- China
- Prior art keywords
- content
- virus infection
- regulator
- eye drop
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 229940012356 eye drops Drugs 0.000 title claims description 10
- 230000009385 viral infection Effects 0.000 claims abstract description 15
- 230000003204 osmotic effect Effects 0.000 claims abstract description 10
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 8
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 8
- 239000000022 bacteriostatic agent Substances 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 210000000744 eyelid Anatomy 0.000 claims abstract description 3
- 230000002207 retinal effect Effects 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 20
- 229930003427 Vitamin E Natural products 0.000 claims description 10
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 10
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 10
- 239000004327 boric acid Substances 0.000 claims description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 229940046009 vitamin E Drugs 0.000 claims description 10
- 235000019165 vitamin E Nutrition 0.000 claims description 10
- 239000011709 vitamin E Substances 0.000 claims description 10
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000007865 diluting Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000006196 drop Substances 0.000 claims description 3
- -1 PH regulator Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 125000005619 boric acid group Chemical group 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- NSENZNPLAVRFMJ-UHFFFAOYSA-N 2,3-dibutylphenol Chemical compound CCCCC1=CC=CC(O)=C1CCCC NSENZNPLAVRFMJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 208000018465 Conjunctival injury Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 206010051559 Corneal defect Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicinal preparations, and particularly relates to a Rudexiwei eye drop, a preparation method and application thereof, wherein the Rudexiwei eye drop comprises 0.1-20.0% (W/V) of Rudexiwei, 0.1-4.0% (W/V) of an osmotic pressure regulator, 0.1-5.0% (W/V) of an antioxidant, 0.1-5.0% (W/V) of a pH regulator, 0.1-1% (W/V) of a bacteriostatic agent and 65.0-99.5% (W/V) of a solvent, and is used for treating eyelid virus infection, conjunctival virus infection, corneal virus infection and retinal virus infection.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an eye drop and a preparation method and application thereof.
Background
Reidesivir (Remdesivir) is a viral RNA-dependent RNA polymerase (rdrp) inhibitor developed by Gilidd Science, Inc. and uses a prodrug design of ProTide in its molecular structure. Previously, the clinically developed indications for reicepvir have all surrounded ebola virus infection. The structural formula is as follows:
reed-civir qualifies as an orphan drug for the treatment of ebola virus infection in the us at 9 months 2015 and in europe at 1 month 2016, respectively. The currently marketed RudeSewei preparation is a freeze-dried preparation, can only be used by injection, and has poor stability and easy color change after long-term storage. For patients with eyes infected by virus, the blood brain barrier is difficult to pass through by in vivo injection, and a preparation capable of directly acting on eyes needs to be developed to make up for the clinical medication requirement.
Disclosure of Invention
Currently marketed Rudexiwei preparations have poor stability, are easy to discolor after being stored for a long time and can only be used by injection. The invention provides a novel eye drop containing the Reidesvir and application of the eye drop in treating ocular virus infection by researching the prescription and process of the eye drop containing the Reidesvir.
A Rudexiluwei eye drop comprises main active components of Rudexiluwei, osmotic pressure regulator, antioxidant, PH regulator, bacteriostatic agent and solvent, wherein the content of the Rudexiluwei is 0.1-20.0% (W/V); the content of the osmotic pressure regulator is 0.1-4.0% (W/V), and the content of the antioxidant is 0.1-5.0% (W/V); the content of the PH regulator is 0.1-5.0% (W/V); the content of the bacteriostatic agent is 0.1-1% (W/V); the content of the solvent is 65.0-99.5% (W/V).
The osmotic pressure regulator is any one of glycerol, sodium chloride and potassium chloride, and the dosage of the osmotic pressure regulator is 0.1-4.0% (W/V); preferably glycerol.
The antioxidant is any one of vitamin E, vitamin C, sodium sulfite, sodium metabisulfite, dibutyl phenol, sodium bisulfite, sodium thiosulfate, tert-butyl p-hydroxyanisole (bha) and dibutyl phenol (bhg), and the dosage of the antioxidant is 0.1-5.0% (W/V), preferably vitamin E.
The pH regulator is any one of boric acid, hydrochloric acid, sodium hydroxide, disodium hydrogen phosphate and sodium dihydrogen phosphate, and the dosage of the pH regulator is 0.1-5.0% (W/V), preferably boric acid.
The bacteriostatic agent is any one of benzalkonium chloride, benzyl alcohol, butyl hydroxybenzoate, phenol and chlorobutanol, and the dosage of the bacteriostatic agent is 0.1-1% (W/V), preferably benzalkonium chloride.
The solvent is selected from medium-chain triglyceride and water for injection, and the dosage of the solvent is 65.0-99.5% (W/V), and preferably the medium-chain triglyceride.
The specification of the eye drop is 1 mg-200 mg/ml.
The preparation method of the Rudexiluwei eye drops comprises the following steps:
adding benzalkonium chloride and boric acid into glycerol, heating to 60 ℃, stirring at a speed of 50rpm for 30min to dissolve;
adding vitamin E and Ruidexilvir, stirring and dissolving;
thirdly, diluting the mixture to the full preparation amount by using sterile medium chain triglyceride, adjusting the pH value to 5.0-7.0 by using 0.1mol/L hydrochloric acid solution, filtering the mixture by using a 0.22 mu m microporous filter membrane, and aseptically filling the mixture into an eye drop bottle to obtain the eye drop.
The application of the Rudexi viruse eye drops is used for treating eyelid virus infection, conjunctival virus infection, corneal virus infection and retinal virus infection.
The active ingredients of the Rudexiluwei eye drops prepared by the invention can be directly absorbed by eyes to focus, and the eye virus infection can be controlled, so that the Rudexiluwei eye drops have the advantages of high bioavailability, good compliance, stable and controllable quality, convenience in carrying and use, suitability for industrial production and the like.
Detailed Description
The following are specific embodiments of the present invention, and the examples are intended to further illustrate the invention and not to limit it. All technical solutions equivalent to the present invention belong to the protection scope of the present invention.
Example 1
| Names of ingredients | Weight(s) |
| Ruidexiwei (Ridexiwei) | 3g |
| Glycerol | 20g |
| Vitamin E | 20g |
| Boric acid | 2g |
| Benzalkonium chloride | 0.5g |
| Medium chain triglycerides | 955ml |
The preparation method comprises the following steps:
adding benzalkonium chloride 0.5g and boric acid 2g into glycerol 20g, heating to 60 deg.C, stirring at 50rpm for 30min to dissolve; then adding 20g of vitamin E and 3g of Reideciclovir, stirring at the speed of 100rpm for 30min to dissolve completely; diluting with sterile medium chain triglyceride 955ml to full dose, adjusting pH to 6.0, filtering with 0.22 μm microporous membrane, and aseptically packaging in eye drop bottle. Each bottle is filled with 10ml, and 100 bottles are filled.
Example 2
The preparation method comprises the following steps:
adding benzalkonium chloride 0.5g and boric acid 4g into glycerol 40g, heating to 60 deg.C, stirring at 50rpm for 20min to dissolve; then adding 20g of vitamin E and 1g of Reidesvir, stirring at the speed of 100rpm for 20min to dissolve completely; diluting with 935ml sterile medium chain triglyceride to full dose, adjusting pH to 5.0, filtering with 0.22 μm microporous membrane, and aseptically packaging in eye drop bottle. Each bottle is filled with 10ml, and 100 bottles are filled.
Example 3
| Name of ingredient | Weight(s) |
| Ruidexiwei (Ridexiwei) | 10g |
| Glycerol | 20g |
| Vitamin E | 40g |
| Boric acid | 1g |
| Benzalkonium chloride | 0.5g |
| Medium chain triglycerides | 929 |
The preparation method comprises the following steps:
adding benzalkonium chloride 0.5g and boric acid 1g into glycerol 20g, heating to 60 deg.C, stirring at 50rpm for 30min to dissolve; then adding 40g of vitamin E and 10g of Reidesvir, stirring at the speed of 100rpm for 50min to dissolve completely; diluting with 929ml sterile medium chain triglyceride to full dose, adjusting pH to 7.0, filtering with 0.22 μm microporous membrane, and aseptically packaging in eye drop bottle. Each bottle is filled with 10ml, and 100 bottles are filled.
Experimental example one drop eye drop stability test
The experimental research method is carried out according to the relevant requirements of Chinese pharmacopoeia, and the stability of the eye drops is tested. The RudeSewei eye drops in the embodiments 1, 2 and 3 are stored for 6 months at 40 +/-2 ℃, and indexes such as properties, osmotic pressure, pH value, related substances, content and the like of the sample are examined at 0 month, 1 month, 2 months, 3 months and 6 months. The relevant parameters were sampled and determined to obtain the corresponding data, as shown in the following table:
TABLE 1 sample test data
The detection data result of the test example proves that the sample prepared by the method has good stability, and the indexes of characters, osmotic pressure, pH value, related substances, content and the like are basically not obviously changed in the placing process, so that the quality of a patient in the using process can be ensured.
Experimental example two
The safety of the ophthalmic formulation of ridciclovir was examined using the samples prepared in example 1. And observing the irritation test of single administration and multiple administrations on the eyes of the rabbits. Before the test, both eyes of each rabbit were examined, rabbits without eye irritation symptom, corneal defect and conjunctival injury were selected, and 24 healthy rabbits were selected, half of them were divided into 8 groups at random. The ophthalmic solution of Ready-Wevir was dropped into the left eye, and the same amount of sterile water for injection was dropped into the right eye, followed by gentle palpebral closure for 20 seconds. The eye local reaction conditions of 0h, 12h, 24h, 48h and 72h after the administration are observed by taking corneal opacity, iris congestion, conjunctival swelling, conjunctival congestion and conjunctival secretion as the investigation indexes. The results are as follows:
the results of the test example show that the Rudexiwei eye drop product has no stimulation to eyes and is applied to ocular virus infection. Can improve the life quality of patients and has wide application value.
Claims (4)
1. A Rudesiwei eye drop is characterized in that: comprises the main active components of Reinecke, osmotic pressure regulator, antioxidant, PH regulator, bacteriostatic agent and solvent, wherein the content of Reinecke is 0.1-20.0% (W/V); the content of the osmotic pressure regulator is 0.1-4.0% (W/V), and the content of the antioxidant is 0.1-5.0% (W/V); the content of the PH regulator is 0.1-5.0% (W/V); the content of the bacteriostatic agent is 0.1-1% (W/V); the content of the solvent is 65.0-99.5% (W/V); wherein the osmotic pressure regulator is glycerol, the antioxidant is vitamin E, the PH regulator is boric acid, the bacteriostatic agent is benzalkonium chloride, and the solvent is medium-chain triglyceride.
2. A radixivir eye drop according to claim 1, characterized in that: the specification of the eye drop is 1 mg-200 mg/ml.
3. A method for preparing ophthalmic rildesavir drops as claimed in claim 1, wherein: the method comprises the following steps:
adding benzalkonium chloride and boric acid into glycerol, heating and stirring for dissolving;
adding vitamin E and Ruidexilvir, stirring and dissolving;
and thirdly, diluting the mixture to the full preparation amount by using sterile medium-chain triglyceride, adjusting the pH value to 5.0-7.0, filtering the mixture through a 0.22 mu m microporous filter membrane, and aseptically filling the mixture into eyedrops to obtain the eyedrops.
4. Use of ophthalmic reed-seivir drops according to claim 1, characterized in that: is used for preparing medicines for treating eyelid virus infection, conjunctival virus infection, corneal virus infection and retinal virus infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110092173.0A CN112656759B (en) | 2021-01-23 | 2021-01-23 | Rudexilvir eye drops and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110092173.0A CN112656759B (en) | 2021-01-23 | 2021-01-23 | Rudexilvir eye drops and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112656759A CN112656759A (en) | 2021-04-16 |
| CN112656759B true CN112656759B (en) | 2022-08-19 |
Family
ID=75414269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110092173.0A Active CN112656759B (en) | 2021-01-23 | 2021-01-23 | Rudexilvir eye drops and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112656759B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023002463A (en) * | 2020-08-28 | 2023-08-18 | Sayvaa Pharmaceuticals Inc | Formulations of anti-viral compounds. |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107929235A (en) * | 2016-10-13 | 2018-04-20 | 沈阳兴齐眼药股份有限公司 | A kind of ophthalmically acceptable preparation of tacrolimus and preparation method thereof |
| US20190083525A1 (en) * | 2017-07-11 | 2019-03-21 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| CN111956630A (en) * | 2020-08-20 | 2020-11-20 | 大连理工大学 | Liquid preparation for atomizer of Reidesciclovir, preparation method and application thereof |
| CN111991375A (en) * | 2020-09-25 | 2020-11-27 | 中国药科大学 | Reed-ciclovir liposome for aerosol inhalation and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210393554A1 (en) * | 2018-11-15 | 2021-12-23 | Bluewillow Biologics, Inc. | Nanoemulsion compositions having enhanced permeability |
-
2021
- 2021-01-23 CN CN202110092173.0A patent/CN112656759B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107929235A (en) * | 2016-10-13 | 2018-04-20 | 沈阳兴齐眼药股份有限公司 | A kind of ophthalmically acceptable preparation of tacrolimus and preparation method thereof |
| US20190083525A1 (en) * | 2017-07-11 | 2019-03-21 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| CN111956630A (en) * | 2020-08-20 | 2020-11-20 | 大连理工大学 | Liquid preparation for atomizer of Reidesciclovir, preparation method and application thereof |
| CN111991375A (en) * | 2020-09-25 | 2020-11-27 | 中国药科大学 | Reed-ciclovir liposome for aerosol inhalation and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2;Brandi N. Williamson et al.;《Nature》;20201209;第585卷(第7824期);第273-276页 * |
| Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing;Sawittree Sahakijpijarn et al.;《Pharmaceutics》;20201022;第12卷(第1002期);第1-28页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112656759A (en) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107456440A (en) | A kind of low concentration atropic category medicament dropping ocular fluid and preparation method thereof | |
| CN107753424B (en) | Preservative-free multi-dose packaged anti-inflammatory eye drops and preparation method thereof | |
| CN111481501B (en) | Ketorolac tromethamine injection capable of reducing irritation and free of organic solvent | |
| CN110974970A (en) | Compound pharmaceutical composition eye drops, preparation method and application thereof | |
| CN106692048A (en) | Single dose eye drop containing polyvinyl alcohol and preparation method thereof | |
| CN112656759B (en) | Rudexilvir eye drops and preparation method and application thereof | |
| CN104997727B (en) | A kind of curcumin micella nasal-cavity administration solution and preparation method thereof | |
| CN105012235B (en) | A kind of ophthalmically acceptable antimycotic nano micellar solution containing terbinafine HCl | |
| CN105125491A (en) | Resveratrol micelle eye drops and preparation method thereof | |
| CN105030669B (en) | A kind of curcumin micelle eye drop and preparation method thereof | |
| CN101474146A (en) | Timolol maleate eye drops without bacteriostatic agent and preparation method thereof | |
| CN116672310A (en) | Ophthalmic composition for improving stability of easily-hydrolyzed medicine, preparation method and application | |
| CN113786380A (en) | A kind of pilocarpine nitrate ophthalmic gel and preparation method thereof | |
| CN101461781A (en) | Gernebcin eye drops without bacteriostatic agent and preparation method thereof | |
| WO2024160252A1 (en) | Low-concentration atropine drug product and manufacturing method therefor | |
| CN102579599B (en) | Decumbent corydalis tuber eye drop and preparation method thereof | |
| CN101455635A (en) | Cromoglyn sodium eye drops without bacteria inhibitor and preparation method thereof | |
| CN111450054B (en) | Ophthalmic preparation containing caffeic acid ester, preparation method and application | |
| CN101455683A (en) | Pearls eyesight-improving eye drops without bacteria inhibitor and preparation method thereof | |
| CN102512362B (en) | Formula and preparation method of compound ciprofloxacin eye drops | |
| CN102008427A (en) | Latanoprost ophthalmic in situ slow release gel | |
| RU2475248C1 (en) | Ophthalmic cross-linking agent-2 | |
| CN117045587A (en) | Preparation of brimonidine tartrate eye temperature-sensitive in-situ gel | |
| CN102512357A (en) | Nerve growth factor ophthalmic gel and preparation method thereof | |
| CN102579600B (en) | Method for preparing decumbent corydalis tuber eye drop and product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |